Supplementary Information

Visible-light photoredox-catalyzed four component reaction for the construction of sulfone-containing quinoxalin-2(1H)-ones

YufenLv,^a JinyunLuo,^a MuzeLin,^a HuilanYue,^b* Bin Dai^a and Lin He^a*

 ^a School of Chemistry and Chemical Engineering, Shihezi University, Xinjiang Uygur Autonomous Region, 832000, China
 ^bQinghai Provincial Key Laboratory of Tibetan Medicine Research and CAS Key Laboratory of Tibetan Medicine Research, Northwest Institute of Plateau Biology, Qinghai 810008, China
 *Corresponding author.
 E-mail: hlyue@nwipb.cas.cn; helin@shzu.edu.cn

Table of Contents

1. General information	S2
2. General procedure for visible-light photoredox-catalyzed four component	reaction
leading to sulfone-containing quinoxalin-2(1H)-ones	S3
3. Preliminary mechanistic studies	. S3-S5
4. Characterization data of products	S6-S15
5. Copies of NMR and HRMS spectra	16-S61

1. General information

All commercially available reagent grade chemicals were purchased from Adamas, Strem, MERYER, Alfa Aesarand Energy Chemical Company and used as received without further purification unless otherwise stated. ¹H NMR and ¹³C NMR were recorded in CDCl₃ on a BrukerAvance III 500MHz or 400 MHz spectrometer with TMS as internal standard at room temperature, the chemical shifts (δ) were expressed in ppm and *J* values were given in Hz. The following abbreviations are used to indicate the multiplicity: singlet (s), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), doublet of triplets (dt), and multiplet (m). All first order splitting patterns were assigned on the basis of the appearance of the multiplet. Splitting patterns that could not be easily interpreted were designated as multiplet (m). High-resolution mass spectra (HRMS) were obtained on an LTQ Orbitrap XL mass spectrometry equipped with an ESI source. Column chromatography was performed on silica gel (200-300 mesh).

2. General procedure for visible-light photoredox-catalyzed four component reaction leading to sulfone-containing quinoxalin-2(1H)-ones.



A mixture of quinoxalin-2(1H)-ones **1** (0.1mmol), aryldiazoniumtetrafluoroborate **3** (0.2mmol), Na₂S₂O₅**4** (0.3mmol), and Rose Bengal (1 mol%), and DCE(2 mL) in a tube (20 mL). Then, the tube was filled with N₂. Alkene **2** (0.2 mmol) and DCE (2 mL) was added in tube under nitrogen atmosphere. The reaction mixture was stirred and irradiated by 3 W blue LEDs at room temperature for 12h. After completion of the reaction, the reaction mixture was concentrated in vacuum. The residue was purified by flash column chromatography using a mixture of petroleum ether and ethyl acetate as eluent to give the desired product **5**.

3. Preliminary mechanistic studies

3.1 The addition of TEMPO in the model reaction system.



A mixture of 1-methylquinoxalin-2(1H)-one (1a), phenyldiazoniumtetrafluoroborate (3a), Na₂S₂O₅ (4), Rose Bengal (1 mol%), and TEMPO (0.2 mmol) in a 20mL tube. Then, the tube was filled with N₂. Styrene 2a (0.2 mmol) and DCE (2 mL) were added in tube under nitrogen atmosphere. The reaction mixture was stirred and irradiated by 3 W blue LEDs at room temperature for 12h. After completion of the reaction, the reaction mixture was concentrated in vacuum. None of the desired product **5a** was detected and TEMPO trapped complexes **A** and **B** were detected by LC-MS. The above result indicated that a radical process should be involved in this reaction.



2. On/off experiments.

phenyldiazoniumtetrafluoroborate (**3a**), Na₂S₂O₅ (**4**), and Rose Bengal (1 mol%) in a 20mL tube. Then, the tube was filled with N₂. Styrene **2a** and DCE (2 mL) were added in tube under nitrogen atmosphere. The reaction mixture was stirred and irradiated by 3 W blue LEDs at room temperature under nitrogen atmosphere for 3h, the corresponding product was isolated in 36% yield. The reaction mixture was stirred and irradiated by 3 W blue LEDs at room temperature under nitrogen atmosphere for 3h, the corresponding product was continuously stirred in the dark for 3h, the desired product was obtained in 36.1% yield. Furthermore, when the reaction mixture was stirred and irradiated by 3 W blue LEDs at room temperature under nitrogen atmosphere for 3h, the desired product was obtained in 57% yield. Moreover, the reaction mixture was stirred and irradiated by 3 W blue LEDs at room temperature under nitrogen atmosphere for 6h, the desired product was isolated in 57% yield. Moreover, the reaction mixture was stirred and irradiated by 3 W blue LEDs at room temperature under nitrogen atmosphere for 6h, then the reaction mixture was continuously stirred in the dark for 3h, the desired product was obtained in 57% yield. Moreover, the reaction mixture was stirred and irradiated by 3 W blue LEDs at room temperature under nitrogen atmosphere for 6h, then the reaction mixture was continuously stirred in the dark for 3h, the desired product was obtained in 57% yield. The above results indicated that the continuous visible light irradiation is essential for promoting this transformation (Fig. S1).



Fig. S1 On/off experiments

4. Characterization data of products



1,6-dimethyl-3-(1-phenyl-2-(phenylsulfonyl)ethyl)-5-vinylpyrazin-2(1H)-one

(5a),¹H NMR (500 MHz, CDCl₃): δ 7.82 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 8.0 Hz, 1H), 7.53 - 7.49(m, 1H), 7.38 - 7.30(m, 6H), 7.21 (t, J = 7.9 Hz, 3H), 7.17 - 7.14 (m, 1H), 5.28 (dd, J_I = 3.4 Hz, J_2 = 10.0 Hz, 1H), 4.79 (dd, J_I = 10.0 Hz, J_2 = 14.4 Hz, 1H), 3.64 (dd, J_I = 3.4 Hz, J_2 = 14.4 Hz, 1H), 3.57 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 157.4, 153.9, 139.4, 138.4, 133.1, 133.0, 132.1, 130.3, 130.1, 128.8, 128.8, 128.3, 127.6, 123.6, 113.5, 59.3, 42.1, 29.1; ESI HRMS: calculated for C₂₃H₂₁N₂O₃S [M+H]⁺ 405.1273, found 405.1261.



1-methyl-3-(1-phenyl-2-tosylethyl)quinoxalin-2(1H)-one (5b), ¹H NMR(500 MHz, CDCl₃): δ 7.74 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.47 (t, J = 7.8 Hz, 1H), 7.34 - 7.30(m, 3H), 7.23 - 7.15 (m, 4H), 7.05 (d, J = 8.2 Hz, 2H), 5.26 (dd, J_1 = 3.0 Hz, J_2 = 10.2 Hz, 1H), 4.78 (dd, J_1 = 10.0 Hz, J_2 = 14.4 Hz, 1H), 3.60 (dd, J_1 = 3.0 Hz, J_2 = 14.4 Hz, 1H), 3.56 (s, 3H), 2.17(s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 157.4, 153.9, 144.2, 138.6, 136.3, 133.0, 132.1, 130.2, 130.0, 129.4, 128.8, 128.4, 128.3, 127.5, 123.5, 113.4, 59.4, 42.1, 29.1, 21.4; ESI HRMS: calculated for C₂₄H₂₃N₂O₃S [M+H]⁺ 419.1429, found 419.1438.



1-methyl-3-(1-phenyl-2-(m-tolylsulfonyl)ethyl)quinoxalin-2(1H)-one (5c), ¹H NMR(500 MHz, CDCl₃): δ 7.76 - 7.74 (m, 1H), 7.62 (d, *J* = 7.8 Hz, 1H), 7.55 (s, 1H), 7.52 - 7.49 (m, 1H), 7.34 (d, *J* = 7.3 Hz, 2H), 7.33 - 7.30(m, 1H), 7.23 - 7.19 (m, 3H), 7.17 - 7.15 (m, 2H), 7.08 (d, *J* = 7.6 Hz, 1H), 5.27 (dd, *J*₁ = 3.4 Hz, *J*₂ = 10.0 Hz, 1H), 4.78 (dd, *J*₁ = 10.2 Hz, *J*₂ = 14.4 Hz, 1H), 3.62 (dd, *J*₁ = 3.0 Hz, *J*₂ = 14.4 Hz, 1H), 3.55 (s, 3H), 2.18 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 157.4, 153.8, 139.2, 139.0, 138.5, 133.8, 133.0, 132.1, 130.3, 130.0, 128.8, 128.7, 128.6, 128.3, 127.5, 125.5, 123.5, 113.4, 59.4, 42.2, 29.1, 21.0; ESI HRMS: calculated for C₂₄H₂₃N₂O₃S [M+H]⁺ 419.1429, found 419.1464.



1-methyl-3-(1-phenyl-2-(o-tolylsulfonyl)ethyl)quinoxalin-2(1H)-one (5d), ¹HNMR(500 MHz, CDCl₃): δ 7.89 - 7.87(m, 1H), 7.76 (d, *J* = 7.9 Hz, 1H), 7.50 (t, *J* = 7.8 Hz, 1H), 7.36 (d, *J* = 7.4 Hz, 2H), 7.31 (t, *J* = 7.6 Hz, 1H), 7.22 (t, *J* = 7.6 Hz, 2H), 7.16 (t, *J* = 7.8 Hz, 2H),7.13 - 7.10 (m, 2H), 6.89 - 6.88 (m, 1H), 5.28 (dd, *J*_{*I*} = 3.4 Hz, *J*₂ = 10.0 Hz, 1H), 4.88 (dd, *J*_{*I*} = 10.0 Hz, *J*₂ = 14.4 Hz, 1H), 3.62 (dd, *J*_{*I*} = 3.0 Hz, *J*₂ = 14.4 Hz, 1H),3.59 (s, 3H), 2.67 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 157.4, 153.7, 138.6, 138.5, 137.1, 133.1, 132.9, 132.2, 131.9, 130.5, 130.3, 129.8, 128.8, 128.3, 127.5, 126.0, 123.5, 113.5, 58.3, 42.0, 29.0, 20.5; ESI HRMS: calculated for C₂₄H₂₂N₂NaO₃S [M+Na]⁺441.1249, found 441.1283.



3-(2-((4-methoxyphenyl)sulfonyl)-1-phenylethyl)-1-methylquinoxalin-2(1H)-one (**5e**),¹H NMR (400 MHz, CDCl₃): δ 7.78 - 7.76 (m, 1H), 7.71 (d, *J* = 8.8 Hz, 2H), 7.53 - 7.49(m, 1H), 7.35 - 7.30(m, 3H), 7.24 - 7.14(m, 4H), 6.69 (d, *J* = 8.8 Hz, 2H), 5.27 (dd,*J*₁ = 3.4 Hz, *J*₂ = 10.0 Hz, 1H), 4.78 (dd,*J*₁ = 10.2 Hz, *J*₂ = 14.4 Hz, 1H), 3.64(s, 3H), 3.62 (dd,*J*₁ = 3.0 Hz, *J*₂ = 14.4 Hz, 1H), 3.56 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 163.2, 157.5, 153.8, 138.6, 133.0, 132.2, 130.7, 130.6, 130.1, 130.0, 128.8, 128.3, 127.5, 123.5, 113.9, 113.4, 59.6, 55.4, 42.2, 29.0; ESI HRMS: calculated for C₂₄H₂₃N₂O₄S [M+H]⁺ 435.1379, found 435.1415.



3-(2-((4-fluorophenyl)sulfonyl)-1-phenylethyl)-1-methylquinoxalin-2(1H)-one

(**5f**),¹H NMR (400 MHz, CDCl₃): δ 7.82 - 7.77 (m, 3H), 7.55 - 7.51(m, 1H), 7.36 - 7.32(m, 3H), 7.23 - 7.16(m, 4H), 6.96 (t, J = 8.6 Hz, 2H), 6.69 (d, J = 8.8 Hz, 2H), 5.27 (dd, $J_I = 3.8$ Hz, $J_2 = 10.0$ Hz, 1H), 4.75 (dd, $J_I = 10.0$ Hz, $J_2 = 14.4$ Hz, 1H), 3.67 (dd, $J_I = 3.8$ Hz, $J_2 = 14.4$ Hz, 1H), 3.58 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 165.4 (d, J = 254.6 Hz), 157.4, 153.8, 138.2, 135.4 (d, J = 3.2 Hz), 133.0, 132.1, 131.2 (d, J = 9.5 Hz), 130.5, 130.0, 128.8, 128.3,127.6, 123.7, 116.0 (d, J = 22.5 Hz), 113.6, 59.5,42.1, 29.1; ESI HRMS: calculated for C₂₃H₂₀FN₂O₃S [M+H]⁺ 423.1179, found 423.1202.



3-(2-((4-chlorophenyl)sulfonyl)-1-phenylethyl)-1-methylquinoxalin-2(1H)-one

(5g), ¹H NMR (400 MHz, CDCl₃): δ 7.76 - 7.74 (m, 1H), 7.70 (d, J = 8.6 Hz, 2H), 7.55 - 7.50 (m, 1H), 7.36 - 7.33 (m, 3H), 7.23 - 7.15 (m, 6H), 6.69 (d, J = 8.8 Hz, 2H), 5.24 (dd, $J_I = 3.4$ Hz, $J_2 = 10.0$ Hz, 1H), 4.76 (dd, $J_I = 10.2$ Hz, $J_2 = 14.4$ Hz, 1H), 3.66 (dd, $J_I = 3.4$ Hz, $J_2 = 14.4$ Hz, 1H), 3.57(s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.2, 153.7, 140.0, 138.2, 137.7, 133.0, 132.0, 130.5, 129.9, 129.0, 128.8, 128.3, 127.6, 123.7, 113.6, 59.5, 42.2, 29.1; ESI HRMS: calculated for C₂₃H₂₀ClN₂O₃S [M+H]⁺ 439.0883, found 439.0901.



3-(2-((4-bromophenyl)sulfonyl)-1-phenylethyl)-1-methylquinoxalin-2(1H)-one (**5h**), ¹H NMR (400MHz, CDCl₃): δ 7.76 - 7.74 (m, 1H), 7.63 (d, *J* = 8.6 Hz, 2H), 7.56 - 7.51 (m, 1H), 7.38 - 7.33 (m, 5H), 7.24 - 7.17 (m, 4H), 6.69 (d, *J* = 8.8 Hz, 2H), 5.24 (dd, *J*₁= 3.4 Hz, *J*₂= 10.0 Hz, 1H), 4.77 (dd, *J*₁ = 10.0 Hz, *J*₂ = 14.4 Hz, 1H), 3.64 (dd, *J*₁ = 3.4 Hz, *J*₂ = 14.4 Hz, 1H), 3.58(s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.2, 153.7, 138.2, 138.1, 132.9, 132.0, 130.5, 130.0, 129.9, 128.8, 128.6, 128.3, 127.6, 123.8, 113.7, 59.4, 42.2, 29.1; ESI HRMS: calculated for C₂₃H₂₀BrN₂O₃S [M+H]⁺ 483.0378, found 483.0412.



Methyl4-((2-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)-2-phenylethyl)sulfonyl) benzoate (5i),¹H NMR(400MHz, CDCl₃): δ 7.91 - 7.84 (m, 4H), 7.71 - 7.69 (m, 1), 7.51 - 7.47 (m, 1H), 7.34 - 7.29 (m, 3H), 7.23 - 7.14 (m, 4H), 5.28 (dd, J_1 = 3.4 Hz, J_2 = 10.0 Hz, 1H), 4.77 (dd, J_1 = 10.1 Hz, J_2 = 14.4 Hz, 1H), 3.89 (s, 3H), 3.67 (dd, J_1 = 3.4 Hz, J_2 = 14.4 Hz, 1H),3.57 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 165.2, 157.1, 153.8, 143.1, 138.1, 134.1, 132.9, 131.9, 130.3, 129.9, 129.9, 128.8, 128.4, 128.3, 127.7, 123.6, 113.5, 59.4, 52.5, 42.1, 29.1; ESI HRMS: calculated for C₂₅H₂₃N₂O₅S [M+H]⁺463.1328, found 463.1306.



1-methyl-3-(1-phenyl-2-((4-(trifluoromethyl)phenyl)sulfonyl)ethyl)quinoxalin-2(1 H)-one (5j),¹H NMR (400 MHz, CDCl₃): δ 7.90 (d, J = 8.2 Hz, 2H), 7.72 - 7.70 (m, 1H), 7.54 - 7.49 (m, 3H), 7.34 - 7.31 (m, 3H), 7.22 - 7.16 (m, 4H), 5.28 (dd, $J_I = 3.4$ Hz, $J_2 = 10.0$ Hz, 1H), 4.77 (dd, $J_I = 10.1$ Hz, $J_2 = 14.4$ Hz, 1H), 3.73 (dd, $J_I = 3.4$ Hz, $J_2 = 14.4$ Hz, 1H), 3.55 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.0, 153.7, 142.8, 137.9, 134.7 (q, J = 33.9 Hz), 132.9, 131.8, 130.6, 129.8, 129.0, 128.8, 128.3, 127.7, 125.8(q, J = 3.6 Hz), 123.8, 113.6, 59.3, 42.2, 29.0; ESI HRMS: calculated for C₂₄H₂₃F₃N₂O₃S [M+H]⁺473.1147, found 473.1150.



1-methyl-3-(2-(phenylsulfonyl)-1-(p-tolyl)ethyl)quinoxalin-2(1H)-one (5k), ¹H NMR (400 MHz, CDCl₃): δ 7.82 - 7.80 (m, 2H), 7.77 - 7.75 (m, 1H), 7.52 - 7.48 (m, 1H), 7.38 - 7.29 (m, 4H), 7.20 (t, *J* = 8.3 Hz, 3H), 7.01 (d, *J* = 8.0 Hz, 2H), 5.24 (dd, *J*₁ = 3.4 Hz, *J*₂ = 10.0 Hz, 1H), 4.77 (dd, *J*₁ = 10.0 Hz, *J*₂ = 14.4 Hz, 1H), 3.63 (dd, *J*₁ = 3.4 Hz, *J*₂ = 14.4 Hz, 1H), 3.56 (s, 3H), 2.23 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.5, 153.9, 139.4, 137.3, 135.4, 133.0, 132.1, 130.2, 130.0, 129.5, 128.8, 128.3, 128.2, 123.5, 113.5, 59.4, 41.8, 29.1, 21.0; ESI HRMS: calculated for C₂₄H₂₃N₂O₃S [M+H]⁺419.1429, found 419.1436.



1-methyl-3-(2-(phenylsulfonyl)-1-(m-tolyl)ethyl)quinoxalin-2(1H)-one (51), ¹H NMR (400 MHz, CDCl₃): δ 7.82 - 7.76 (m, 3H), 7.53 - 7.49 (m, 1H), 7.38 - 7.29 (m, 4H), 7.20 (d, *J* = 8.2 Hz, 1H), 7.13 - 7.07 (m, 3H) 6.96 (d, *J* = 7.0 Hz, 1H), 5.24 (dd, *J*₁ = 3.4Hz, *J*₂ = 10.0 Hz, 1H), 4.78 (dd, *J*₁ = 10.0 Hz, *J*₂ = 14.4 Hz, 1H), 3.63 (dd, *J*₁ = 3.4 Hz, *J*₂ = 14.4 Hz, 1H), 3.57 (s, 3H), 2.23 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.5, 153.9, 139.4, 138.4, 138.3, 133.0, 133.0, 132.1, 130.2, 130.1, 129.0, 128.8, 128.6, 128.3, 125.3, 123.5, 113.5, 59.4, 42.0, 29.1, 21.4. ESI HRMS: calculated for C₂₄H₂₃N₂O₃S [M+H]⁺419.1429, found 419.1416.



3-(1-(4-(tert-butyl)phenyl)-2-(phenylsulfonyl)ethyl)-1,6-dimethyl-5-vinylpyrazin-2(1H)-one (5m),¹H NMR (400 MHz, CDCl₃): δ 7.82 - 7.76 (m, 3H), 7.52 -7.48 (m, 1H), 7.35 - 7.28 (m, 4H), 7.24 - 7.18 (m, 5H), 5.26 (dd, J_1 = 3.4 Hz, J_2 = 10.0 Hz, 1H), 4.78 (dd, J_1 = 10.0 Hz, J_2 = 14.4 Hz, 1H), 3.66 (dd, J_1 = 3.4 Hz, J_2 = 14.4 Hz, 1H),3.57 (s, 3H), 1.22 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 157.6, 153.9, 150.3, 139.4, 135.3, 133.0, 132.2, 130.2, 130.0, 128.8, 128.3, 127.9, 125.7, 123.5, 113.4, 59.3, 41.6, 34.4, 31.2, 29.1; ESI HRMS: calculated for $C_{27}H_{29}N_2O_3S$ [M+H]⁺ 461.1899, found 461.1967.



3-(1-(4-fluorophenyl)-2-(phenylsulfonyl)ethyl)-1-methylquinoxalin-2(1H)-one (**5n**), ¹H NMR (400 MHz, CDCl₃): δ 7.81 - 7.76 (m, 3H), 7.55 - 7.51 (m, 1H), 7.40 - 7.28 (m, 6H), 7.22 (d, *J* = 8.3 Hz, 1H), 6.88 (t, *J* = 8.7 Hz, 2H), 5.27 (dd, *J*₁ = 4.1 Hz, *J*₂ = 10.0 Hz, 1H), 4.69 (dd, *J*₁ = 10.0 Hz, *J*₂ = 14.4 Hz, 1H), 3.65 (dd, *J*₁ = 4.1 Hz, *J*₂ = 14.4 Hz, 1H), 3.58 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 162.1 (d, *J* = 245.1 Hz), 157.3, 153.8, 139.3, 134.0(d, *J* = 3.2 Hz), 133.1, 133.0, 132.1, 130.4, 130.0 (d, *J* = 9.3 Hz), 128.9, 128.3, 123.6, 115.6 (d, *J* = 21.4 Hz), 113.5, 59.3, 41.4, 29.1; ESI HRMS: calculated for C₂₃H₂₀FN₂O₃S [M+H]⁺423.1179, found 423.1196.



3-(1-(4-bromophenyl)-2-(phenylsulfonyl)ethyl)-1-methylquinoxalin-2(1H)-one

(50), ¹H NMR (400 MHz, CDCl₃): δ 7.80 - 7.76 (m, 3H), 7.55 - 7.51 (m, 1H), 7.41 - 7.38 (m, 1H), 7.35 - 7.30 (m, 5H), 7.21 (t, *J* = 8.1 Hz, 3H), 5.24 (dd, *J*₁ = 4.3 Hz, *J*₂ = 9.2 Hz, 1H), 4.67 (dd, *J*₁ = 9.2 Hz, *J*₂ = 14.4 Hz, 1H), 3.66 (dd, *J*₁ = 4.3 Hz, *J*₂ = 14.4 Hz, 1H),3.58 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.0, 153.8, 139.3, 137.3, 133.2, 133.0, 132.1, 131.8, 130.5, 130.1, 130.1, 128.9, 128.2, 123.7, 121.7, 113.6, 59.1, 41.7, 29.1; ESI HRMS: calculated for C₂₃H₂₀BrN₂O₃S [M+H]⁺483.0378, found 483.0392.



3-(1-(3-fluorophenyl)-2-(phenylsulfonyl)ethyl)-1-methylquinoxalin-2(1H)-one

(**5p**),¹H NMR (500 MHz, CDCl₃): δ 7.81 (d, J = 7.3 Hz, 2H), 7.77 (d, J = 7.9 Hz, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.39 - 7.37 (m, 1H), 7.34 - 7.32 (m, 3H), 7.22 (d, J = 8.4 Hz, 1H), 7.19 - 7.13 (m, 2H), 7.01 (d, J = 9.8 Hz, 1H), 6.87 - 6.83 (m, 1H), 5.28 (dd, J_I = 3.8 Hz, J_2 = 10.0 Hz, 1H), 4.71 (dd, J_I = 10.0 Hz, J_2 = 14.4 Hz, 1H), 3.64 (dd, J_I = 3.8 Hz, J_2 = 14.4 Hz, 1H),3.58 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 162.8 (d, J = 245.3 Hz), 156.9, 153.8, 140.8 (d, J = 7.2 Hz), 139.2, 133.2, 133.1, 132.1, 130.6, 130.3 (d, J = 8.2 Hz), 130.1, 128.9, 128.3, 124.2 (d, J = 2.8 Hz), 123.7, 115.2 (d, J = 21.9 Hz), 114.6 (d, J = 20.9 Hz), 113.6, 59.2, 41.8, 29.2; ESI HRMS: calculated for C₂₃H₂₀FN₂O₃S [M+H]⁺ 423.1179, found 423.1222.



3-(1-(3-chlorophenyl)-2-(phenylsulfonyl)ethyl)-1-methylquinoxalin-2(1H)-one(5q), ¹H NMR (400 Hz, CDCl₃): δ 7.81 - 7.78 (m, 3H), 7.53 (t, J = 7.3 Hz, 2H), 7.39 - 7.32 (m, 4H), 7.26 - 7.21 (m, 3H), 7.17 - 7.11 (m, 2H), 5.25 (dd, $J_1 = 4.1$ Hz, $J_2 = 10.0$ Hz, 1H), 4.69 (dd, $J_1 = 10.0$ Hz, $J_2 = 14.4$ Hz, 1H), 3.65 (dd, $J_1 = 4.1$ Hz, $J_2 = 14.4$ Hz, 1H), 3.59 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 156.9, 153.8, 140.3, 139.3, 134.5, 133.2, 132.1, 130.6, 130.2, 130.0, 128.9, 128.3, 128.3, 127.8, 126.8, 123.7, 113.6, 59.1, 41.8, 29.2; ESI HRMS: calculated for C₂₃H₂₀ClN₂O₃S [M+H]⁺439.0883, found 439.0920.



3-(1-(4-chlorophenyl)-2-(phenylsulfonyl)ethyl)-1-methylquinoxalin-2(1H)-one(5r), ¹H NMR (500 Hz, CDCl₃): δ 7.79 - 7.75 (m, 3H), 7.54- 7.51 (m, 1H), 7.40 - 7.37 (m, 1H), 7.34 - 7.31 (m, 3H), 7.26 (d, *J* = 8.5 Hz, 2H), 7.21 (d, *J* = 8.4 Hz, 1H), 7.16 (d, *J* = 8.5 Hz, 2H), 5.25 (dd, *J*₁ = 4.3 Hz, *J*₂ = 9.2 Hz, 1H), 4.67 (dd, *J*₁ = 9.2 Hz, *J*₂ = 14.4 Hz, 1H), 3.66 (dd, *J*₁ = 4.3 Hz, *J*₂ = 14.4 Hz, 1H),3.57 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 157.1, 153.8, 139.3, 136.8, 133.5, 133.2, 133.0, 132.1, 130.5, 130.1, 129.8, 128.9, 128.9, 128.3, 123.7, 113.6, 59.2, 41.6, 29.2; ESI HRMS: calculated for C₂₃H₂₀ClN₂O₃S [M+H]⁺439.0883, found 439.0854.



4-(1-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)-2-(phenylsulfonyl)ethyl)benzon itrile(5s),¹H NMR (400 Hz, CDCl₃): δ 7.81 - 7.77 (m, 3H), 7.58 - 7.54 (m, 1H), 7.51 - 7.45 (m, 4H), 7.44 - 7.40 (m, 1H), 7.37 - 7.33 (m, 3H), 7.24 (d, *J* = 8.5 Hz, 1H), 5.33 (dd, *J*₁ = 4.7 Hz, *J*₂ = 8.8 Hz, 1H), 4.64 (dd, *J*₁ = 8.8 Hz, *J*₂ = 14.4 Hz, 1H), 3.69 (dd, *J*₁ = 4.7 Hz, *J*₂ = 14.4 Hz, 1H), 3.59 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 156.4, 153.7, 143.6, 139.2, 133.4, 133.1, 132.5, 132.0, 130.9, 130.1, 129.3, 129.0, 128.2, 123.9, 118.5, 113.7, 111.5, 58.8, 42.3, 29.2; ESI HRMS: calculated for C₂₄H₂₀N₃O₃S [M+H]⁺ 430.1225, found 430.1237.



1-methyl-3-(2-(phenylsulfonyl)-1-(4-trifluoromethyl)phenyl)ethyl)quinoxalin-2(1 H)-one(5t), ¹H NMR (400Hz, CDCl₃): δ 7.80 - 7.77 (m, 3H), 7.56 - 7.52 (m, 1H), 7.47 - 7.43 (m, 4H), 7.41 - 7.30 (m, 4H), 7.23 (d, J = 8.3 Hz, 1H),5.35 (dd, $J_I = 4.6$ Hz, $J_2 = 8.9$ Hz, 1H), 4.68 (dd, $J_I = 8.9$ Hz, $J_2 = 14.4$ Hz, 1H), 3.72 (dd, $J_I = 4.6$ Hz, $J_2 = 14.4$ Hz, 1H), 3.59 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 156.8, 153.8, 142.2, 139.2, 133.3, 133.1, 132.1, 130.7, 130.1, 129.8 (d, J = 32.3 Hz), 128.9, 128.8, 128.2, 125.6 (q, J = 3.7 Hz), 123.9 (d, J = 270.5 Hz), 123.8, 113.6, 59.0, 42.1, 29.2; ESI HRMS: calculated for C₂₄H₂₃F₃N₂O₃S [M+H]⁺ 473.1147, found 473.1121.



1-methyl-3-(2-(phenylsulfonyl)-1-(o-tolyl)ethyl)quinoxalin-2(1H)-one(5u), ¹H NMR (400 Hz, CDCl₃): δ 7.87 - 7.81 (m, 3H), 7.55 - 7.51 (m, 1H), 7.41 - 7.32 (m, 4H), 7.22 (d, *J* = 8.3 Hz, 1H), 7.13 (d, *J* = 7.3 Hz, 1H), 7.08 - 7.03 (m, 2H), 6.96 (t, *J* = 7.4 Hz, 1H), 5.48 (dd, *J*₁ = 2.6 Hz, *J*₂ = 10.3 Hz, 1H), 4.79 (dd, *J*₁ = 10.3 Hz, *J*₂ = 14.4 Hz, 1H), 3.58 (s, 3H), 3.41 (dd, *J*₁ = 2.6 Hz, *J*₂ = 14.4 Hz, 1H), 2.48 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.6, 154.1, 139.1, 136.9, 136.8, 133.1, 133.0, 132.0, 131.0, 130.3, 130.1, 128.9, 128.4, 127.4, 127.1, 126.1, 123.6, 113.5, 59.2, 37.4, 29.1, 19.5; ESI HRMS: calculated for C₂₄H₂₃N₂O₃S [M+H]⁺419.1429, found 419.1413.



1-methyl-3-(1-phenyl-3-(phenylsulfonyl)propan-2-yl)quinoxalin-2(1H)-one(5v), ¹H NMR (400 Hz, CDCl₃): δ 7.77 - 7.74 (m, 1H), 7.70 - 7.68 (m, 2H), 7.56 - 7.52 (m, 1H), 7.39 - 7.31 (m, 2H), 7.30 - 7.24 (m, 3H), 7.19 - 7.15 (m, 3H), 7.08 - 7.06 (m, 2H), 4.33 - 4.27 (m, 1H), 4.25 - 4.21 (m, 1H), 3.64 (s, 3H), 3.28 (dd, J_I = 1.8 Hz, J_2 = 13.9 Hz, 1H), 3.13 (dd, J_I = 5.1 Hz, J_2 = 13.9 Hz, 1H), 2.69 (d, J_I = 9.7 Hz, J_2 = 13.9 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 158.9, 154.1, 133.0, 132.9, 132.3, 130.3, 129.9, 129.1, 128.7, 128.6, 128.3, 126.7, 123.6, 113.5, 56.1, 39.0, 38.9, 29.1; ESI HRMS: calculated for C₂₄H₂₃N₂O₃S [M+H]⁺419.1429, found 419.1397.



1-methyl-3-(4-phenyl-1-(phenylsulfonyl)butan-2-yl)quinoxalin-2(1H)-one(5w), ¹H NMR (400 Hz, CDCl₃): δ 7.81 - 7.79 (m, 2H), 7.76 - 7.74 (m, 1H), 7.55 - 7.50 (m, 1H), 7.41 - 7.37 (m, 1H), 7.32 (t, J = 7.4 Hz, 3H), 7.21 (d, J = 8.4 Hz, 1H), 7.15 (t, J = 7.2 Hz, 2H), 7.09 - 7.07 (m, 1H), 7.04 (d, J = 8.2 Hz, 2H), 4.31 (dd, J_1 = 10.0 Hz, J_2 = 14.4 Hz, 1H), 4.06 - 4.02 (m, 1H), 3.58 (s, 3H), 3.40 (dd, J_1 = 3.1 Hz, J_2 = 14.4 Hz, 1H), 2.68 - 2.60 (m, 1H), 2.53 - 2.46 (m, 1H), 2.23 - 2.15 (m, 1H), 2.02 - 1.93 (m, 1H);

¹³C NMR (100 MHz, CDCl₃): δ 159.2, 154.2, 140.9, 139.1, 133.1, 133.0, 132.2, 130.2, 129.9, 128.8, 128.4, 128.3, 128.2, 125.9, 123.5, 113.4, 58.3, 37.5, 35.2, 33.1, 29.0; ESI HRMS: calculated for C₂₅H₂₅N₂O₃S [M+H]⁺ 433.1586, found 433.1580.



1-ethyl-3-(1-phenyl-2-(phenylsulfonyl)ethyl)quinoxalin-2(1H)-one(5x), ¹H NMR (500 Hz, CDCl₃): δ 7.81 - 7.80 (m, 2H), 7.77 - 7.75 (m, 1H), 7.52 - 7.48 (m, 1H), 7.34 - 7.26 (m, 6H), 7.21 (t, *J* = 7.3 Hz, 3H), 7.16 (t, *J* = 7.2 Hz, 1H), 5.30 - 5.27 (m, 1H), 4.82 - 4.77 (m, 1H), 4.26 - 4.18 (m, 1H), 4.16 - 4.08 (m, 1H), 3.66 - 3.63 (m, 1H), 1.29 (t, *J* = 7.2 Hz, 3H) ; ¹³C NMR (125 MHz, CDCl₃): δ 157.4, 153.3, 139.3, 138.6, 133.1, 132.4, 131.9, 130.3, 130.3, 128.9, 128.8, 128.3, 127.5, 123.3, 113.3, 59.4, 42.0, 37.5, 12.3; ESI HRMS: calculated for C₂₄H₂₃N₂O₃S [M+H]⁺ 419.1429, found 429.1426.



1-butyl-3-(1-phenyl-2-(phenylsulfonyl)ethyl)quinoxalin-2(1H)-one (5y), ¹H NMR (400 Hz, CDCl₃): δ 7.95-7.89 (m ,1H),7.82-7.79 (m, 2H), 7.76 (dd, $J_l = 1.3$ Hz, $J_2 = 8.0$ Hz,1H), 7.52-7.46 (m, 1H), 7.34 - 7.26 (m, 6H), 7.22-7.15 (m, 3H), 5.28 (dd, $J_l = 3.4$ Hz, $J_2 = 10.0$ Hz,1H), 4.78 (dd, $J_l = 10.0$ Hz, $J_2 = 14.4$ Hz,1H), 4.20-4.12 (m, H), 4.07-3.99 (m, 1H), 3.64 (dd, $J_l = 3.4$ Hz, $J_2 = 14.4$ Hz,1H), 1.69-1.61 (m, 2H), 1.47-1.40 (m, 2H), 0.97 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.4, 153.6, 139.4, 138.6, 133.0, 132.4, 132.2, 130.3, 130.2, 128.9, 128.8, 128.8, 128.3, 127.4, 123.3, 113.5, 59.4, 42.3, 42.0, 29.2, 20.3, 13.8. ESI HRMS: calculated for C₂₆H₂₇N₂O₃S [M+H]⁺ 447.1742, found 447.1750.



1-benzyl-3-(1-phenyl-2-(phenylsulfonyl)ethyl)quinoxalin-2(1H)-one(5z), ¹H NMR (400 Hz, CDCl₃): δ 7.82 (d, J = 7.1 Hz, 2H), 7.74 (dd, J_l = 1.4 Hz, J_2 = 8.0 Hz,1H), 7.38-7.33 (m, 3H), 7.26 - 7.23 (m, 9H), 7.18-7.15 (m, 4H), 5.46 (d, J = 15.6 Hz, 1H), 5.35 (dd, J_l = 3.4 Hz, J_2 = 10.0 Hz,1H), 5.22 (d, J = 15.6 Hz, 1H), 4.81 (dd, J_l = 10.0 Hz, J_2 = 14.4 Hz,1H), 3.66 (dd, J_l = 3.4 Hz, J_2 = 14.4 Hz,1H); ¹³C NMR (100 MHz, CDCl₃): δ 157.6, 154.1, 139.4, 138.5, 135.1, 133.2, 132.4, 132.3, 130.3, 130.2, 128.9, 128.9, 128.8, 128.3, 127.8, 127.6, 127.0, 123.6, 114.3, 59.4, 46.0, 42.2. ESI HRMS: calculated for C₂₉H₂₅N₂O₃S [M+H]⁺ 481.1586, found 481.1595.



1,6,7-trimethyl-3-(1-phenyl-2-(phenylsulfonyl)ethyl)quinoxalin-2(1H)-one(5a'),

¹H NMR (400 Hz, CDCl₃): δ 7.82 - 7.80 (m, 2H), 7.54 (s, 1H), 7.39 - 7.36 (m, 1H), 7.34 - 7.30 (m, 4H), 7.21 - 7.14 (m, 3H), 6.96 (s, 1H), 5.24 (dd, J_1 = 3.7 Hz, J_2 = 9.8 Hz, 1H), 4.75 (dd, J_1 = 10.0 Hz, J_2 = 14.4 Hz, 1H), 3.64 (dd, J_1 = 3.7 Hz, J_2 = 14.4 Hz, 1H), 3.54 (s, 3H), 2.40 (s, 3H), 2.34 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 156.1, 153.9, 140.1, 139.4, 138.7, 133.0, 132.4, 131.1, 130.6, 130.1, 128.8, 128.7, 128.3, 128.3, 127.4, 114.0, 59.4, 42.0, 29.0, 20.6, 19.1; ESI HRMS: calculated for C₂₅H₂₅N₂O₃S [M+H]⁺433.1586, found 433.1596.



1-methyl-3-(1-phenyl-2-(phenylsulfonyl)ethyl)-6-(trifluoromethyl)quinoxalin-2(1 H)-one(5b'), ¹H NMR (400 Hz, CDCl₃): δ 8.04 (s, 1H), 7.84 - 7.82 (m, 2H), 7.75 - 7.72 (m, 1H), 7.44 - 7.30 (m, 6H), 7.25 - 7.15 (m, 4H), 5.31 (dd, J_1 = 3.2 Hz, J_2 = 10.4 Hz, 1H), 4.75 (dd, J_1 = 10.4 Hz, J_2 = 14.4 Hz, 1H), 3.64(dd, J_1 = 3.2 Hz, J_2 = 14.4 Hz, 1H), 3.62 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.4, 153.8, 139.5, 137.8, 135.4, 133.3, 131.4, 128.9 (q, J = 9.9 Hz), 128.3, 128.3, 127.8, 127.5, 127.4 (q, J = 3.8 Hz), 126.6 (q, J = 3.4 Hz), 125.8 (q, J = 45.6 Hz), 122.3, 114.2, 59.2, 42.1, 29.4; ESI HRMS: calculated for C₂₄H₂₃F₃N₂O₃S [M+H]⁺473.1147, found 473.1177.



6-chloro-1-methyl-3-(1-phenyl-2-(phenylsulfonyl)ethyl)quinoxalin-2(1H)-one(5c'), ¹H NMR (400 Hz, CDCl₃): δ 7.81 (d, J = 7.4 Hz, 2H), 7.68 (d, J = 8.4 Hz, 1H), 7.46 -7.28 (m, 6H), 7.23-7.15 (m, 4H), 5.25 (d, J = 9.9 Hz, 1H), 4.77 - 4.71 (dd, J_I =10.5Hz, J_2 =14.4Hz, 1H), 3.62 (d, J = 14.4 Hz, 1H), 3.53 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.6, 153.6, 139.3, 138.2, 136.3, 133.9, 133.2, 131.1, 130.6, 128.9, 128.8, 128.3, 128.3, 127.7, 124.0, 113.6, 59.2, 42.0, 29.3. ESI HRMS: calculated for C₂₃H₂₀ClN₂O₃S [M+H]⁺439.0883, found 439.0883.



6-fluoro-1-methyl-3-(1-phenyl-2-(phenylsulfonyl)ethyl)quinoxalin-2(1H)-one(5d'), ¹H NMR (400Hz, CDCl₃): δ 7.84 - 7.82 (m, 2H), 7.49 - 7.46 (m, 1H), 7.41 - 7.31 (m, 5H), 7.27 - 7.15 (m, 5H), 5.29 (dd, J_1 = 3.3 Hz, J_2 = 10.2 Hz, 1H), 4.75 (dd, J_1 =10.2 Hz, $J_2 = 14.4$ Hz, 1H), 3.63 (dd, $J_1 = 3.3$ Hz, $J_2 = 14.4$ Hz, 1H), 3.58 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.1, 158.6 (d, J = 242.5 Hz), 153.6, 139.4, 138.1, 133.2, 132.6 (d, J = 11.2 Hz), 129.7 (d, J = 2.0 Hz), 128.9, 128.8, 128.3, 128.3, 127.7, 118.0 (d, J = 23.8 Hz), 115.4 (d, J = 22.3 Hz), 114.6 (d, J = 8.7 Hz), 59.2, 42.1, 29.4; ESI HRMS: calculated for C₂₃H₂₀FN₂O₃S [M+H]⁺ 423.1179, found 423.1186.

5. Copies of NMR and HRMS spectra



S19

7.7626 7.7595 7.7595 7.7595 7.7595 7.7595 7.7515 7.7515 7.7515 7.7515 7.7515 7.7515 7.7515 7.7515 7.7515 7.7515 7.75175 7.75175 7.75175 7.75175 7.75175 7.75175 7.75175 7.752757 7.7527575 7.7527575 7.752757575 7.7527575757575757575

7.9142 7.7240 7.77240 7.77240 7.77240 7.75041 7.75041 7.55197 7.55197 7.55197 7.55197 7.55197 7.55197 7.7329 7.73291 7.73291 7.732910 7.73260 7.732910 7.73210 7.73210 7.73210 7.732000 7.732000 7.732000 7.732000000000

S32

-156.3023 -156.3023 -153.7566 -133.7576 -133.3759 -132.0313 -132.0313 -132.0314 -132.0314 -132.0314 -132.0314 -123.8846 -111.5026 -111.5026 -111.5026 -111.5026 -111.5026 -111.5026 -111.5026 -111.5026 -22.707

7.7967 7.77812 7.77812 7.75648 7.75648 7.5564 7.5564 7.7564 7.7564 7.7564 7.7564 7.7564 7.7470 7.7470 7.7470 7.7470 7.7470 7.7470 7.7470 7.7389 7.73846 7.73846 7.73846 7.73846 7.73846 7.73846 7.73846 7.73846 7.73846 7.73846 7.73846 7.73846 7.73846 7.73846 7.738567 7.738567 7.738567 7.738567 7.738567 7.738567 7.738567 7.738567 7.738567 7.738567 7.738567 7.7385767 7.738567 7.738567 7.738567 7.7385777777777777777777777777

3.03-1 1.08-1

3.5 3.0

13 8 9 5

2.0 1.5 1.0 0.5 0.0

2.5

1.00 H

4. 0

6.0 5.5 f1 (ppm) 5.0 4.5

2200 3.07 2.09 2.09 2.09 2.09 2.09

7.5 7.0 6.5

8. 0

9.0 8.5

1.5 11.0 10.5 10.0 9.5

P. 17, 2008. P. 17, 2008. P. 17, 2019. P. 17, 2010. P. 17, 2010. P. 17, 2010. P. 2010. P.

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

25.080 27.080 27.080 27.081 27.081 27.081 27.081 27.081 27.081 27.080

